Sarepta to expedite timeline for muscular dystrophy gene therapyR&D, TherapeuticsThe company’s original plan was to not apply to regulators until 2023, but now, it plans to submit the drug to the FDA in the next few months, with plans to launch the drug in mid-2023. Read more August 4, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2021/02/FDA-Approves-Third-Sarepta-Treatment-For-Duchenne-Muscular-Dystrophy-BioSpace-2-26-21.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-08-04 09:51:142022-08-04 10:15:59Sarepta to expedite timeline for muscular dystrophy gene therapy